Jpmorgan Chase & CO Aurinia Pharmaceuticals Inc. Transaction History
Jpmorgan Chase & CO
- $1.23 Trillion
- Q4 2024
A detailed history of Jpmorgan Chase & CO transactions in Aurinia Pharmaceuticals Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 927,298 shares of AUPH stock, worth $7.46 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
927,298
Previous 502,816
84.42%
Holding current value
$7.46 Million
Previous $3.69 Million
125.97%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding AUPH
# of Institutions
227Shares Held
58.9MCall Options Held
949KPut Options Held
1.51M-
Black Rock Inc. New York, NY9.27MShares$74.6 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA8.43MShares$67.9 Million5.69% of portfolio
-
Armistice Capital, LLC New York, NY6.4MShares$51.5 Million0.81% of portfolio
-
Nea Management Company, LLC Timonium, MD3.97MShares$32 Million2.55% of portfolio
-
State Street Corp Boston, MA2.92MShares$23.5 Million0.0% of portfolio
About Aurinia Pharmaceuticals Inc.
- Ticker AUPH
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 141,892,000
- Market Cap $1.14B
- Description
- Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...